Literature DB >> 12408442

Probiotics--role in inflammatory bowel disease.

P Gionchetti1, C Amadini, F Rizzello, A Venturi, V Palmonari, C Morselli, R Romagnoli, M Campieri.   

Abstract

The aetiology of inflammatory bowel disease is still unclean. Whilst a specific pathogen agent associated with these diseases has not been found, the rationale for probiotic therapy in inflammatory bowel disease is based on convincing evidence involving intestinal bacteria in their pathogenesis. Encouraging results have been obtained with probiotic therapy in several animal models of experimental colitis. The administration of highly concentrated probiotic preparations represents a valid approach both for the prevention of pouchitis onset and relapses. The encouraging results obtained in ulcerative colitis and Crohn's disease need to be further assessed in large double-blind trials.

Entities:  

Mesh:

Year:  2002        PMID: 12408442     DOI: 10.1016/s1590-8658(02)80166-9

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  9 in total

1.  Preventing recurrent acute diverticulitis with pharmacological therapies.

Authors:  Antonio Tursi
Journal:  Ther Adv Chronic Dis       Date:  2013-11       Impact factor: 5.091

Review 2.  Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease.

Authors:  Antonio Tursi; Raymond E Joseph; Paul Streck
Journal:  Dig Dis Sci       Date:  2011-05-13       Impact factor: 3.199

3.  Diverticular disease: A therapeutic overview.

Authors:  Antonio Tursi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-02-06

4.  Recommendations for improved use of the murine TNBS-induced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria: technical and microbiological aspects.

Authors:  Benoit Foligné; Sophie Nutten; Lothar Steidler; Véronique Dennin; Denise Goudercourt; Annick Mercenier; Bruno Pot
Journal:  Dig Dis Sci       Date:  2006-02       Impact factor: 3.199

5.  Effects of probiotic on intestinal mucosa of patients with ulcerative colitis.

Authors:  Hai-Hong Cui; Cun-Long Chen; Ji-De Wang; Yu-Jie Yang; Yong Cun; Jin-Bao Wu; Yu-Hu Liu; Han-Lei Dan; Yan-Ting Jian; Xue-Qing Chen
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

6.  Yoghurts containing probiotics reduce disruption of the small intestinal barrier in methotrexate-treated rats.

Authors:  E Southcott; K L Tooley; G S Howarth; G P Davidson; R N Butler
Journal:  Dig Dis Sci       Date:  2008-04-22       Impact factor: 3.199

7.  Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon.

Authors:  Antonio Tursi; Giovanni Brandimarte; Gian Marco Giorgetti; Walter Elisei; Fabio Aiello
Journal:  Int J Colorectal Dis       Date:  2007-03-28       Impact factor: 2.571

Review 8.  Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis.

Authors:  F Lirussi; E Mastropasqua; S Orando; R Orlando
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

9.  Comparative secretome analysis of four isogenic Bacillus clausii probiotic strains.

Authors:  Rosa Lippolis; Rosa Anna Siciliano; Maria Fiorella Mazzeo; Anna Abbrescia; Antonio Gnoni; Anna Maria Sardanelli; Sergio Papa
Journal:  Proteome Sci       Date:  2013-07-01       Impact factor: 2.480

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.